奥麦罗制药 OMER 深 沪
等待开盘 04-02 09:30:00 美东时间
12.08
+1.520
+14.39%
华盛通- 最 高13.00
- 今 开11.32
- 成交量 462.69万股
- 最 低 11.29
- 昨 收 10.56
- 总市值 8.56亿
- 52周最高 17.65
- 市盈率 静 --
- 换手率 6.53%
- 52周最低 2.95
- 委 比 -97.85%
- 总股本 7090.05万
- 历史最高 30.23
- 量 比 4.68
- 振 幅 16.19%
- 历史最低 0.92
- 每 手 1
- 风险率 3.59%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Omeros rises as Novo deal boosts Q4 earnings
Omeros Corporation (OMER) added ~14%, posting its best intraday gain since December on Wednesday after the company reported better-than-expected earnings with its Q4 2025 financials, thanks mainly to ...
今天 02:09
Omeros Q4 Adj. EPS $3.14 Beats $(0.57) Estimate
Omeros (NASDAQ:OMER) reported quarterly earnings of $3.14 per share which beat the analyst consensus estimate of $(0.57) by 650.88 percent. This is a 598.41 percent increase over losses of $(0.63) per share from the same
04-01 04:06
Earnings Scheduled For March 31, 2026
Companies Reporting Before The Bell • Bitfarms (NASDAQ:BITF) is projected to re...
03-31 19:11
Omeros Q4 2025 Earnings Preview
Omeros (OMER) is scheduled to announce Q4 earnings results on Monday, March 30th, after market close. The consensus EPS Estimate is $0.36 (+166.7% Y/Y) and the consensus Revenue Estimate is $0M Over t...
03-31 05:35
Omeros updates its financial calendar; management hosts a conference call and webcast for FY2025 results
Omeros updates its financial calendar; management hosts a conference call and webcast for FY2025 results Omeros will release financial results for the fourth quarter and year ended Dec. 31, 2025 on March 31, 2026 after market close. A conference call and webcast is scheduled for March 31, 2026 at 4:
03-26 20:45
Omeros to host EBMT industry session on TA-TMA treatment advances
Omeros to host EBMT industry session on TA-TMA treatment advances Omeros will host an industry session at the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) on March 22, 2026, from 2:30pm to 4pm CET in Madrid. The session is titled “Advances in TA-TMA Treatme
03-21 15:23
Omeros Completes Initial Trial In Nonhuman Primates To Evaluate OncotoX-AML Cancer Therapeutic Platform
Omeros Corporation (NASDAQ: OMER) today announced the successful completion of its initial study in nonhuman primates evaluating the efficacy and safety of its OncotoX-AML cancer therapeutic platform. Omeros' OncotoX-AML
02-17 21:46
Omeros Reports Successful Primate Study of OncotoX-AML for Leukemia Treatment
Omeros Reports Successful Primate Study of OncotoX-AML for Leukemia Treatment Omeros Corporation announced the successful completion of an initial nonhuman primate study evaluating its OncotoX-AML therapeutic platform for acute myeloid leukemia (AML). The study demonstrated a marked, selective, and
02-17 21:45
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. ...
02-05 01:35
